# Allay Therapeutics

**Canonical:** https://apis.io/providers/allay-therapeutics/  
**Website:** https://www.allaytx.com/  
**APIs profiled:** 8

Allay Therapeutics is a clinical-stage biopharmaceutical company with operations in San Jose, California and Singapore, developing ultra-sustained, non-opioid analgesic products for post-surgical pain management. Its platform is a tunable drug-biopolymer architecture that pairs validated non-opioid analgesics with dissolvable biopolymers to release pain relief at a targeted surgical site over weeks rather than days, and can be tuned for constant release (chronic pain such as osteoarthritis) or pulsed release (cyclic pain such as gout). Lead candidate ATX-101 is a bupivacaine-based implant placed directly at the surgical site during total knee replacement (TKA), targeting the three-day to two-week analgesia gap that drives breakthrough pain and opioid use; it holds FDA Breakthrough Therapy Designation and entered a pivotal Phase 2b registration trial with first patients dosed in 2025. Additional programs (ATX-201, ATX-301, ATX-401, ATX-501) span new formulations, injectables, additional clinical indications and on-demand anesthetic delivery. The company raised a $57.5M Series D plus a venture debt line in 2025 and has a development and commercialization agreement with Maruishi Pharmaceutical for Japan. It is a therapeutics developer, not a software company, and publishes no developer program, API, SDK, or machine-readable interface.

## Kin Score — 30.2 / 100 (thin)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 30.2).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 54.9 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 12.5 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 30.0 (agent-aware)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (8)

- **Allay Therapeutics Comments API** — Comment collection. Registered and anonymously reachable, but empty — X-WP-Total is 0.
- **Allay Therapeutics Discovery API** — Route, type, taxonomy and status discovery documents.
- **Allay Therapeutics Media API** — Media library. `X-WP-Total` reports 161 attachments, but only one attachment (id 1503) is returned to an anonymous caller; the remainder are attached to non-public parents.
- **Allay Therapeutics Oembed API** — oEmbed 1.0 provider endpoint for www.allaytx.com URLs.
- **Allay Therapeutics Pages API** — Corporate pages. 9 published at harvest time — Home, About Us, Our Science, Pipeline, News, Careers, Contact Us, Privacy Notices, Terms of Service.
- **Allay Therapeutics Posts API** — News archive — press releases, in-the-news coverage, and presentations/publications. 19 posts published at harvest time, spanning 2021-05-13 (company launch with first clinical ...
- **Allay Therapeutics Search API** — Cross-content search across published posts and pages.
- **Allay Therapeutics Taxonomy API** — Categories and tags. Four categories are registered — Press Releases (14), In The News (4), Presentations and Publications (1), Uncategorized (0). The post_tag taxonomy holds th...

## Security (2)

- **Allay Therapeutics Authentication** — 0 schemes
- **Allay Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Biotechnology, Pharmaceuticals, Pain Management, Drug Delivery, Non-Opioid, Clinical Stage, Health, Life Sciences, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/allay-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.